The purpose of this Clinical Oncology Research Career Development Program is to facilitate interdisciplinary training in clinical and translational oncology research for physicians and doctoral degreed nurses with a clinical training background in one of a number of oncology disciplines, including medical, surgical, pediatric, radiation and nursing ontology. This training program is supported by robust interdisciplinary clinical and translation research programs in the Comprehensive Cancer Center of Case Western Reserve and University Hospitals of Cleveland that provide trainees the opportunity to pursue mentored research experiences along one of four clinical research themes: Mechanism Based Therapeutics, Hematopoietic Stem Cell Therapeutics, Genetic Oncology, and Behavioral and Clinical Health Services. The trainee develops and pursues an individual mentored research experience under co-mentors who include a basic investigator and a clinical investigator. Tile mentored research experience is enhanced by a 2-year didactic curriculum that is designed to provide basic background and highly individualized advanced training in both clinical and methodological components of clinical and translational cancer research. This curriculum is sufficiently flexible to accommodate the diverse backgrounds and interests of trainees. Trainees may elect to expand the didactic component of the curriculum to obtain a Masters of Science Degree in Clinical Research. This training is supplemented by the resources of an institutional K30 award, and other NCI-supported training programs that create a highly interactive critical mass of translational and clinical trainees. The ultimate goal of he program is to provide clinical MD/DO and doctoral degreed RN oncologists with the skills, experience and confidence to pursue independent and collaborative careers in clinical cancer research, thereby increasing the likelihood that basic/behavioral research findings will be applied to clinical cancer care in a creative and timely manner. The success of this program wilt be measured by the output of clinical oncologists that pursue careers dedicated to clinical research and discovery.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA076917-08
Application #
6773232
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
1997-09-30
Project End
2007-06-30
Budget Start
2004-08-20
Budget End
2005-06-30
Support Year
8
Fiscal Year
2004
Total Cost
$587,949
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Arbesman, Joshua; Ravichandran, Sairekha; Funchain, Pauline et al. (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell Melanoma Res 31:529-533
Saygin, Caner; Hirsch, Cassandra; Przychodzen, Bartlomiej et al. (2018) Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J 8:4
Ye, Rebecca; Tomlinson, Benjamin; de Lima, Marcos et al. (2018) Timing Embryo Preservation for a Patient with High-Risk Newly Diagnosed Acute Myeloid Leukemia. Case Rep Hematol 2018:9807047
Stahl, Maximilian; DeVeaux, Michelle; de Witte, Theo et al. (2018) The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv 2:1765-1772
Conic, Ruzica Z; Arbesman, Joshua (2018) Melanoma Tumor Characteristics: An Analysis of Mutational Burden and Copy Number Alterations by Patient Age and Stage. J Invest Dermatol 138:1218-1221
Rambhia, Pooja H; Honda, Kord; Arbesman, Joshua (2018) Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient. Melanoma Res 28:475-477
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Pan, Feng; Wingo, Thomas S; Zhao, Zhigang et al. (2017) Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells. Nat Commun 8:15102
Doherty, Mary R; Cheon, HyeonJoo; Junk, Damian J et al. (2017) Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc Natl Acad Sci U S A 114:13792-13797
Negoro, Eiju; Nagata, Yasunobu; Clemente, Michael J et al. (2017) Origins of myelodysplastic syndromes after aplastic anemia. Blood 130:1953-1957

Showing the most recent 10 out of 88 publications